Abstract
Cumulative damage to lung tissue by leukocyte elastase is thought to be responsible for the development of pulmonary emphysema, an irreversible lung disease characterized by loss of lung elasticity1–3. It is also thought to be involved in the rapidly developing and usually fatal adult respiratory distress syndrome4. The primary defence against elastase damage is the anti-protease known as α1-antitrypsin5,6, a glycosylated serum protein of 394 amino acids3. Oxidation of the methionine 358 residue located at the active centre of α1-antitrypsin results in a dramatic decrease in inhibitory activity towards elastase which effectively inactivates the protective function6. It has been suggested that this oxidation sensitivity has a regulatory function and allows tissue breakdown at sites of inflammation by inactivation of α1-antitrypsin by oxygen radicals released by phagocytes3. In the above diseases, however, the oxidative inactivation of α1-antitrypsin is probably of major importance in allowing lung damage by elastase4,7. An oxidation-resistant α1-antitrypsin might make it possible to reduce the large doses of α1-antitrypsin required for emphysemics and provide treatment for acute inflammatory respiratory conditions. To further the possibility of therapy for the above conditions, we describe here the synthesis in yeast of active, non-glycosylated, human α1-antitrypsin. Site-directed mutagenesis has been used to construct an active, oxidation-resistant derivative containing a single methionine to valine substitution at the active centre. This demonstrates the potential of engineered modifications to protein molecules designed to improve their physiological function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Eriksson, S. Acta med. scand. 175, 197–205 (1964).
Lancet i, 743–745 (1980).
Carrell, R. W. et al. Nature 298, 329–334 (1982).
Cochrane, C. G., Spragg, R. G., Revak, S. D., Cohen, A. B. & McGuire, W. W. Am. Rev. resp. Dis. 127, Suppl. 2, 25–27 (1983).
Laurell, C.-B. & Eriksson, S. Scand. J. clin. Lab. Invest. 15, 132–140 (1963).
Beatty, K., Bieth, J. & Travis, J. J. biol. Chem. 255, 3931–3934 (1980).
Gadek, J. E., Fells, G. A. & Crystal, R. G. Science 206, 1315–1316 (1979).
Kurachi, K. et al. Proc. natn. Acad. Sci. U.S.A. 78, 6826–6830 (1981).
Leicht, M. et al. Nature 297, 655–659 (1982).
Suggs, S. V., Wallace, R. B., Hirose, T., Kawashima, E. H. & Itakura, K. Proc. natn. Acad. Sci. U.S.A. 78, 6613–6617 (1981).
Ish-Horowicz, D. & Burke, J. F. Nucleic Acids Res. 9, 2989–2998 (1981).
Sanger, F., Nicklen, S. & Coulson, A. R. Proc. natn. Acad. Sci. U.S.A. 74, 5463–5467 (1977).
Messing, J. Meth. Enzym. 101, 20–78 (1983).
Fagerhol, M. K. & Cox, D. W. Adv. hum. Genet. 11, 1–62 (1981).
Bolivar, F. et al. Gene 2, 95–113 (1977).
Meyhack, B., Bajwa, W., Rudolph, H. & Hinnen, A. EMBO J. 6, 675–680 (1982).
Kramer, R. A., DeChiara, T. M., Schaber, M. D. & Hilliker, S. Proc. natn. Acad. Sci. U.S.A. 81, 367–370 (1984).
Holland, M. J. & Holland, J. P. J. biol. Chem. 254, 5466–5474 (1979).
Zoller, M. J. & Smith, M. Nucleic Acids Res. 10, 6487–6500 (1982).
Villafranca, J. E. et al. Science 222, 782–788 (1984).
Brake, A. J. et al. Proc. natn. Acad. Sci. U.S.A. 81, 4642–4646 (1984).
Hinnen, A., Hicks, J. B. & Fink, G. R. Proc. natn. Acad. Sci. U.S.A. 75, 1929–1933 (1978).
Hemmings, B. A., Zubenko, G. S., Hasilik, A. & Jones, E. W. Proc. natn. Acad. Sci. U.S.A. 78, 435–439 (1981).
Johnson, D. & Travis, J. J. biol. Chem. 253, 7142–7144 (1978).
Gadek, J. E. & Crystal, R. G. Am. Rev. resp. Dis. 127, Suppl. 2, 45–46 (1983).
Jeppson, J-O., Laurell, C-B. & Fagerhol, M. K. Eur. J. Biochem. 83, 143–153 (1978).
Jeppson, J-O., Laurell, C-B., Nosslin, B. & Cox, D. W. Clin. Sci. molec. Med. 5, 103–107 (1978).
Urdea, M. S. et al. Proc. natn. Acad. Sci. U.S.A. 80, 7461–7465 (1983).
Nakajima, K., Powers, J. C., Ashe, B. M. & Zimmerman, M. J. biol. Chem. 254, 4027–4032 (1979).
Owen, M. C., Brennan, S. O., Lewis, J. H. & Carrell, R. W. New Engl. J. Med. 694–698 (1983).
Loebermann, H., Tokuoka, R., Deisenhofer, J. & Huber, R. J. molec. Biol. (in the press).
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. & Hall, B. D. Nature 298, 347–350 (1982).
Bradford, M. Analyt. Biochem. 72, 248–253 (1976).
Baugh, R. J. & Travis, J. Biochemistry 15, 836–841 (1976).
Bollen, A. et al. DNA 2, 255–264 (1983).
Martial, J. A., Hallewell, R. A., Baxter, J. D. & Goodman, H. M. Science 205, 602–607 (1979).
Maniatis, T., Fritsch, E. F. & Sambrook, J. Molecular Cloning (Cold Spring Harbor Laboratory, New York, 1982).
Porter, A. G. et al. Nature 282, 471–477 (1979).
Burke, R. L., Tekamp-Olson, P. & Najarian, R. J. biol. Chem. 258, 2193–2201 (1983).
Beggs, J. D. Nature 275, 104–109 (1978).
Boyer, H. W. & Roulland-Dussoix, D. J. molec. Biol. 41, 459–472 (1969).
Laemmli, U. K. Nature 227, 680–685 (1977).
Towbin, H., Staehelin, T. & Gordon, J. Proc. natn. Acad. Sci. U.S.A. 76, 4350–4355 (1979).
Sherman, F. et al. Methods in Yeast Genetics (Cold Spring Harbor Laboratory, New York, 1982).
Rubin, G. M. Meth. Cell Biol. 12, 45–64 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosenberg, S., Barr, P., Najarian, R. et al. Synthesis in yeast of a functional oxidation-resistant mutant of human α1-antitrypsin. Nature 312, 77–80 (1984). https://doi.org/10.1038/312077a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/312077a0
This article is cited by
-
Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use
Amino Acids (2006)
-
Evolution of murine ?1-proteinase inhibitors: Gene amplification and reactive center divergence
Journal of Molecular Evolution (1994)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.